Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirtobrutinib - Loxo Oncology

Next Previous
X
Search
Drug Profile

Pirtobrutinib - Loxo Oncology

Alternative Names: Jaypirca; LOXO-305; LY 3527727; RXC-005

Latest Information Update: 01 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Redx Pharma
  • Developer Eli Lilly and Company; Loxo Oncology
  • Class Amides; Amines; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase II Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Marginal zone B-cell lymphoma
  • Phase I Haematological malignancies

Most Recent Events

  • 24 Jun 2024 Registered for Mantle-cell lymphoma (Second-line therapy or greater) in Japan (PO)
  • 27 Mar 2024 Loxo Oncology and Eli Lilly and Company withdrew a phase II trial prior to enrollment, in Multiple sclerosis (In adults) in USA and Puerto Rico (PO), due to a sponsor decision (NCT06104683)
  • 25 Mar 2024 Nippon Shinyaku and Eli Lilly Japan enters into an alliance agreement in Japan for pirtobrutinib for mantle cell lymphoma and chronic lymphocytic leukemia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top